이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

진행 전 감지 가능한 ESR1m이 있는 HR+/HER2-MBC에서 AZD9833+ CDK4/6 억제제를 평가하기 위한 3상 연구(SERENA-6) (SERENA-6)

2026년 9월 22일 업데이트: AstraZeneca

HR+/에서 AZD9833(차세대, 경구 SERD) + CDK4/6 억제제(팔보시클립 또는 아베마시클립) 대 지속적인 아로마타제 억제제(레트로졸 또는 아나스트로졸)+ CDK4/6 억제제로의 전환을 평가하기 위한 3상, 이중 맹검, 무작위 연구 Aromatase Inhibitor+ CDK4/6 Inhibitor-A ctDNA Guided Early Switch Study로 1L 치료하는 동안 질병 진행 없이 검출 가능한 ESR1 돌연변이가 있는 HER2-MBC 환자

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with CDK4/6 inhibitor in patients with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2-negative (HER2-negative) metastatic breast cancer with detectable ESR1 mutation.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

Breast cancer is the most common type of cancer among women. In people with breast cancer, the body is not able to control the growth of some cells. These extra cells can form tumors in the breast. When tumor cells move to different parts of the body this is called advanced cancer. Researchers are looking for better ways to treat advanced breast cancer.

This trial will look at six drugs: palbociclib, abemaciclib, ribociclib, letrozole, anastrozole, and AZD9833. AZD9833 is the trial drug, and is the only drug not yet approved for use. Palbociclib, abemaciclib and ribociclib work in the same way and are a type of cancer drug called a CDK4/6 inhibitor. Letrozole and anastrozole work in the same way and are both a type of cancer drug called an aromatase inhibitor (AI). CDK4/6 inhibitors and AIs work together to block the tumor's ability to grow. These drugs have been approved for combined use in people with advanced breast cancer that is HR-positive and HER2-negative. But if people get mutations in the ESR1 gene, it can make the AI and CDK4/6 inhibitor treatment work less well.

The trial drug, AZD9833, is designed to work with a CDK4/6 inhibitor in the same way that an AI does. Researchers think that AZD9833 might work better with a CDK4/6 inhibitor than an AI does in people who get mutations in their ESR1 gene.

Participants in this trial will have already been receiving one of the following combinations of a CDK4/6 inhibitor and an AI:

  • palbociclib + anastrozole
  • palbociclib + letrozole
  • abemaciclib + anastrozole
  • abemaciclib + letrozole
  • ribociclib + anastrozole
  • ribociclib + letrozole

During the trial, participants will remain on the same CDK4/6 inhibitor that they were taking before the trial.

In this trial, the researchers want to find out how well switching a participant with an ESR1 gene mutation from an AI (letrozole or anastrozole) to AZD9833 works in the treatment of advanced breast cancer that is HR-positive and HER2-negative.

The researchers will look at which trial treatment helps the participants live longer with the cancer before it gets worse.

The researchers also want to know more about how safe AZD9833 is.

The trial participants will be split into 2 groups:

  • Participants in Group A will receive AZD9833, a CDK4/6 inhibitor, and a placebo
  • Participants in Group B will receive an AI, a CDK4/6 inhibitor, and a placebo

A placebo looks like a treatment but does not have any medicine in it.

A computer program will be used to randomly choose the treatments each participant gets. This helps make sure the groups are chosen fairly. Researchers do this so that comparing the results of each treatment will be as accurate as possible.

The participants will take their trial treatments over 28-day cycles, with a placebo and either AZD9833 or an AI taken once daily by mouth for all 28 days. If the participant is taking abemaciclib, they will take it twice daily by mouth for all 28 days. If the participant is taking palbociclib or ribociclib, they will take it once daily by mouth for 21 days and then stop taking it for the final 7 days of the cycle. The participant will then repeat the 28-day cycle receiving the trial treatment in the same way for as long as they are in the trial.

Participants will visit their trial site regularly throughout the trial. At these visits, the trial doctors will check the health of the participants. They will also take blood samples and do scans of the participants' tumors.

Participants will take their trial treatment until their cancer gets worse or they decide to leave the trial.

연구 유형

중재적

등록 (실제)

315

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Drammen, 노르웨이, 3004
        • Research Site
      • Oslo, 노르웨이, 0450
        • Research Site
      • Kaohsiung City, 대만, 833
        • Research Site
      • Taichung, 대만, 40705
        • Research Site
      • Tainan, 대만, 70403
        • Research Site
      • Tainan, 대만, 710
        • Research Site
      • Taipei, 대만, 100
        • Research Site
      • Taipei, 대만
        • Research Site
      • Taipei, 대만, 11490
        • Research Site
      • Taipei, 대만, 23561
        • Research Site
      • Taipei, 대만, 11259
        • Research Site
      • Taipei, 대만, 110
        • Research Site
      • Taoyuan, 대만, 333
        • Research Site
      • Cheonan-si, 대한민국, 31151
        • Research Site
      • Daegu, 대한민국, 42415
        • Research Site
      • Goyang-si, 대한민국, 10408
        • Research Site
      • Seongnam-si, 대한민국, 13620
        • Research Site
      • Seongnam-si, 대한민국, 463-712
        • Research Site
      • Seoul, 대한민국, 02841
        • Research Site
      • Seoul, 대한민국, 03080
        • Research Site
      • Seoul, 대한민국, 03722
        • Research Site
      • Seoul, 대한민국, 05505
        • Research Site
      • Seoul, 대한민국, 06273
        • Research Site
      • Seoul, 대한민국, 06351
        • Research Site
      • Seoul, 대한민국, 06591
        • Research Site
      • Ansbach, 독일, 91522
        • Research Site
      • Augsburg, 독일, 86156
        • Research Site
      • Bonn, 독일, 53111
        • Research Site
      • Chemnitz, 독일, 09116
        • Research Site
      • Dresden, 독일, 01307
        • Research Site
      • Erlangen, 독일, 91054
        • Research Site
      • Essen, 독일, 45130
        • Research Site
      • Freiburg im Breisgau, 독일, 79110
        • Research Site
      • Hösbach, 독일, 63768
        • Research Site
      • Immenstadt im Allgäu, 독일, 87509
        • Research Site
      • Koblenz, 독일, 56068
        • Research Site
      • Leipzig, 독일, 4103
        • Research Site
      • Mannheim, 독일, 68167
        • Research Site
      • München, 독일, 80634
        • Research Site
      • Paderborn, 독일, 33098
        • Research Site
      • Ratingen, 독일, 40878
        • Research Site
      • Ravensburg, 독일, 88212
        • Research Site
      • Regensburg, 독일, 93053
        • Research Site
      • Stade, 독일, 21680
        • Research Site
      • Tübingen, 독일, 72076
        • Research Site
      • Ulm, 독일, 89075
        • Research Site
      • Moscow, 러시아 제국, 111123
        • Research Site
      • Moscow, 러시아 제국, 143423
        • Research Site
      • Moscow, 러시아 제국, 129090
        • Research Site
      • Nizhny Novgorod, 러시아 제국, 603126
        • Research Site
      • Podolsk, 러시아 제국, 142100
        • Research Site
      • Saint Petersburg, 러시아 제국, 197758
        • Research Site
      • Saint Petersburg, 러시아 제국, 194017
        • Research Site
    • Arizona
      • Phoenix, Arizona, 미국, 85054
        • Research Site
    • Arkansas
      • Hot Springs, Arkansas, 미국, 71913
        • Research Site
      • Little Rock, Arkansas, 미국, 72205
        • Research Site
    • California
      • Long Beach, California, 미국, 90806
        • Research Site
      • San Diego, California, 미국, 92123
        • Research Site
      • Santa Rosa, California, 미국, 92805
        • Research Site
    • Colorado
      • Grand Junction, Colorado, 미국, 81501
        • Research Site
      • Lone Tree, Colorado, 미국, 80124
        • Research Site
    • Florida
      • Fort Myers, Florida, 미국, 33901
        • Research Site
      • Jacksonville, Florida, 미국, 32256
        • Research Site
      • Jacksonville, Florida, 미국, 32224
        • Research Site
      • St. Petersburg, Florida, 미국, 33705
        • Research Site
    • Georgia
      • Atlanta, Georgia, 미국, 30318
        • Research Site
      • Atlanta, Georgia, 미국, 30322
        • Research Site
      • Atlanta, Georgia, 미국, 30342
        • Research Site
    • Illinois
      • Park Ridge, Illinois, 미국, 60068
        • Research Site
    • Indiana
      • Fort Wayne, Indiana, 미국, 46804
        • Research Site
      • Indianapolis, Indiana, 미국, 46250
        • Research Site
    • Maryland
      • Baltimore, Maryland, 미국, 21202
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Research Site
      • Fairhaven, Massachusetts, 미국, 02719
        • Research Site
      • Foxborough, Massachusetts, 미국, 02035
        • Research Site
      • Milford, Massachusetts, 미국, 01757
        • Research Site
      • South Weymouth, Massachusetts, 미국, 02190
        • Research Site
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • Research Site
      • Grand Rapids, Michigan, 미국, 49503
        • Research Site
    • Minnesota
      • Rochester, Minnesota, 미국, 55905
        • Research Site
    • Mississippi
      • Oxford, Mississippi, 미국, 38655
        • Research Site
    • Missouri
      • Kansas City, Missouri, 미국, 64111
        • Research Site
      • St Louis, Missouri, 미국, 63110
        • Research Site
    • Montana
      • Billings, Montana, 미국, 59101
        • Research Site
    • Nebraska
      • Omaha, Nebraska, 미국, 68130
        • Research Site
    • New Jersey
      • Camden, New Jersey, 미국, 08103
        • Research Site
      • Ridgewood, New Jersey, 미국, 07450
        • Research Site
    • New York
      • Brooklyn, New York, 미국, 11215
        • Research Site
      • East Syracuse, New York, 미국, 13057
        • Research Site
      • New Hyde Park, New York, 미국, 11042
        • Research Site
      • New York, New York, 미국, 10065
        • Research Site
      • New York, New York, 미국, 11355
        • Research Site
      • Shirley, New York, 미국, 11967
        • Research Site
    • North Carolina
      • Goldsboro, North Carolina, 미국, 27534
        • Research Site
    • Ohio
      • Canton, Ohio, 미국, 44710
        • Research Site
      • Cincinnati, Ohio, 미국, 45220
        • Research Site
      • Columbus, Ohio, 미국, 43219
        • Research Site
    • Oregon
      • Portland, Oregon, 미국, 97213
        • Research Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, 미국, 19104
        • Research Site
      • Pittsburgh, Pennsylvania, 미국, 15213
        • Research Site
      • York, Pennsylvania, 미국, 17403
        • Research Site
    • South Carolina
      • Greenville, South Carolina, 미국, 29607
        • Research Site
      • West Columbia, South Carolina, 미국, 29169
        • Research Site
    • Tennessee
      • Knoxville, Tennessee, 미국, 37916
        • Research Site
      • Memphis, Tennessee, 미국, 38120
        • Research Site
      • Nashville, Tennessee, 미국, 37203
        • Research Site
    • Texas
      • Bedford, Texas, 미국, 76022
        • Research Site
      • Dallas, Texas, 미국, 75246
        • Research Site
      • Houston, Texas, 미국, 77030
        • Research Site
      • Houston, Texas, 미국, 77024
        • Research Site
      • Longview, Texas, 미국, 75601
        • Research Site
      • San Antonio, Texas, 미국, 78240
        • Research Site
    • Utah
      • Salt Lake City, Utah, 미국, 84106
        • Research Site
    • Virginia
      • Midlothian, Virginia, 미국, 23114
        • Research Site
      • Norfolk, Virginia, 미국, 23502
        • Research Site
    • Washington
      • Tacoma, Washington, 미국, 98405
        • Research Site
    • Wisconsin
      • Waukesha, Wisconsin, 미국, 53226
        • Research Site
      • Leuven, 벨기에, 3000
        • Research Site
      • Liège, 벨기에, 4000
        • Research Site
      • Namur, 벨기에, 5000
        • Research Site
      • Haskovo, 불가리아, 6300
        • Research Site
      • Panagyurishte, 불가리아, 4500
        • Research Site
      • Pleven, 불가리아, 5804
        • Research Site
      • Plovdiv, 불가리아, 4004
        • Research Site
      • Sofia, 불가리아, 1431
        • Research Site
      • Sofia, 불가리아, 1407
        • Research Site
      • Sofia, 불가리아, 1527
        • Research Site
      • Sofia, 불가리아, 1330
        • Research Site
      • Sofia, 불가리아, 1303
        • Research Site
      • Bern, 스위스, CH-3010
        • Research Site
      • Chur, 스위스, CH-7000
        • Research Site
      • Winterthur, 스위스, 8401
        • Research Site
      • A Coruña, 스페인, 15009
        • Research Site
      • Badalona, 스페인, 08003
        • Research Site
      • Barcelona, 스페인, 8035
        • Research Site
      • L'Hospitalet de Llobregat, 스페인, 08908
        • Research Site
      • Madrid, 스페인, 28041
        • Research Site
      • Madrid, 스페인, 28040
        • Research Site
      • Murcia, 스페인, 30008
        • Research Site
      • Málaga, 스페인, 29010
        • Research Site
      • Sant Joan Despí, 스페인, 08970
        • Research Site
      • Seville, 스페인, 41013
        • Research Site
      • Valencia, 스페인, 46010
        • Research Site
      • Banská Bystrica, 슬로바키아, 974 01
        • Research Site
      • Bratislava, 슬로바키아, 833 01
        • Research Site
      • Košice, 슬로바키아, 041 91
        • Research Site
      • Michalovce, 슬로바키아, 07101
        • Research Site
      • Partizánske, 슬로바키아, 958 01
        • Research Site
      • Blackpool, 영국, FY3 8NR
        • Research Site
      • Cambridge, 영국, CB2 0QQ
        • Research Site
      • London, 영국, SW3 6JJ
        • Research Site
      • London, 영국, WC1N 3BG
        • Research Site
      • Manchester, 영국, M20 4BX
        • Research Site
      • Newport, 영국, NP10 8FZ
        • Research Site
      • Nottingham, 영국, NG5 1PB
        • Research Site
      • Portsmouth, 영국, PO6 3LY
        • Research Site
      • Reading, 영국, RG2 9LH
        • Research Site
      • Sheffield, 영국, S10 2SJ
        • Research Site
      • Sutton, 영국, SM2 5PT
        • Research Site
      • Taunton, 영국, TA1 5DA
        • Research Site
      • Graz, 오스트리아, 8036
        • Research Site
      • Innsbruck, 오스트리아, 6020
        • Research Site
      • Salzburg, 오스트리아, 5020
        • Research Site
      • Vienna, 오스트리아, 1130
        • Research Site
      • Beersheba, 이스라엘, 8410101
        • Research Site
      • Haifa, 이스라엘, 3109601
        • Research Site
      • Jerusalem, 이스라엘, 91120
        • Research Site
      • Petah Tikva, 이스라엘, 494142
        • Research Site
      • Ramat Gan, 이스라엘, 5262000
        • Research Site
      • Bergamo, 이탈리아, 24127
        • Research Site
      • Bologna, 이탈리아, 40138
        • Research Site
      • Florence, 이탈리아, 50134
        • Research Site
      • Meldola, 이탈리아, 47014
        • Research Site
      • Milan, 이탈리아, 20141
        • Research Site
      • Milan, 이탈리아, 20132
        • Research Site
      • Misterbianco, 이탈리아, 95045
        • Research Site
      • Naples, 이탈리아, 80131
        • Research Site
      • Padova, 이탈리아, 35128
        • Research Site
      • Roma, 이탈리아, 00168
        • Research Site
      • Rozzano, 이탈리아, 20089
        • Research Site
      • Chiba, 일본, 260-8717
        • Research Site
      • Chūōku, 일본, 104-0045
        • Research Site
      • Hidaka-shi, 일본, 350-1298
        • Research Site
      • Hirakata-shi, 일본, 573-1191
        • Research Site
      • Kitaadachi-gun, 일본, 362-0806
        • Research Site
      • Kumamoto, 일본, 860-8556
        • Research Site
      • Kōtoku, 일본, 135-8550
        • Research Site
      • Matsuyama, 일본, 791-0280
        • Research Site
      • Nagoya, 일본, 464-8681
        • Research Site
      • Nagoya, 일본, 467-8602
        • Research Site
      • Niigata, 일본, 951-8566
        • Research Site
      • Osaka, 일본, 540-0006
        • Research Site
      • Osaka, 일본, 541-8567
        • Research Site
      • Ota-shi, 일본, 373-8550
        • Research Site
      • Sapporo, 일본, 003-0804
        • Research Site
      • Shinagawa-ku, 일본, 142-8666
        • Research Site
      • Shinjuku-ku, 일본, 162-8655
        • Research Site
      • Takasaki-shi, 일본, 370-0829
        • Research Site
      • Takatsuki-shi, 일본, 569-8686
        • Research Site
      • Tsukuba, 일본, 305-8577
        • Research Site
      • Yokohama, 일본, 241-8515
        • Research Site
    • Alberta
      • Calgary, Alberta, 캐나다, T2N 5G2
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, 캐나다, V5Z 4E6
        • Research Site
    • Ontario
      • Ottawa, Ontario, 캐나다, K1H 8L6
        • Research Site
    • Quebec
      • Lévis, Quebec, 캐나다, G6V 3Z1
        • Research Site
      • Montreal, Quebec, 캐나다, H2X 0C1
        • Research Site
      • Montreal, Quebec, 캐나다, H3T 1E2
        • Research Site
      • Montreal, Quebec, 캐나다, H1T 2M4
        • Research Site
      • Québec, Quebec, 캐나다, G1S 4L8
        • Research Site
      • Adana, 터키 (Türkiye), 01120
        • Research Site
      • Ankara, 터키 (Türkiye), 06100
        • Research Site
      • Ankara, 터키 (Türkiye), 06520
        • Research Site
      • Ankara, 터키 (Türkiye), 06010
        • Research Site
      • Ankara, 터키 (Türkiye), 06340
        • Research Site
      • Cordaleo, 터키 (Türkiye), 35575
        • Research Site
      • Izmir, 터키 (Türkiye), 35100
        • Research Site
      • Izmir, 터키 (Türkiye), 35360
        • Research Site
      • Kadıkoy/Istanbul, 터키 (Türkiye), 34722
        • Research Site
      • Kayseri, 터키 (Türkiye), 38039
        • Research Site
      • Guimarães, 포르투갈, 4835-044
        • Research Site
      • Lisbon, 포르투갈, 1649-035
        • Research Site
      • Lisbon, 포르투갈, 1400-038
        • Research Site
      • Lisbon, 포르투갈, 1500-650
        • Research Site
      • Lisbon, 포르투갈, 1449-005
        • Research Site
      • Loures, 포르투갈, 2674-514
        • Research Site
      • Porto, 포르투갈, 4099-001
        • Research Site
      • Porto, 포르투갈, 4200-319
        • Research Site
      • Porto, 포르투갈, 4200-072
        • Research Site
      • Vila Nova de Gaia, 포르투갈, 4434-502
        • Research Site
      • Bydgoszcz, 폴란드, 85-796
        • Research Site
      • Gdynia, 폴란드, 81-519
        • Research Site
      • Koszalin, 폴란드, 75-581
        • Research Site
      • Lodz, 폴란드, 90-302
        • Research Site
      • Poznan, 폴란드, 60-693
        • Research Site
      • Rzeszów, 폴란드, 35-001
        • Research Site
      • Tomaszów Mazowiecki, 폴란드, 97-200
        • Research Site
      • Warsaw, 폴란드, 02-781
        • Research Site
      • Avignon, 프랑스, 84918
        • Research Site
      • Brest, 프랑스, 29200
        • Research Site
      • Clermont-Ferrand, 프랑스, 63050
        • Research Site
      • Dijon, 프랑스, 21079
        • Research Site
      • Limoges, 프랑스, 83000
        • Research Site
      • Lorient, 프랑스, 56322
        • Research Site
      • Lyon, 프랑스, 69373
        • Research Site
      • Marseille, 프랑스, 13273
        • Research Site
      • Metz-Tessy, 프랑스, 74370
        • Research Site
      • Nîmes, 프랑스, 30029
        • Research Site
      • Paris, 프랑스, 75248
        • Research Site
      • Rouen, 프랑스, 76021
        • Research Site
      • Saint-Cloud, 프랑스, 92210
        • Research Site
      • Saint-Herblain, 프랑스, 44805
        • Research Site
      • Toulouse, 프랑스, 31100
        • Research Site
      • Tours, 프랑스, 37000
        • Research Site
      • Vandœuvre-lès-Nancy, 프랑스, 54519
        • Research Site
      • Vantoux, 프랑스, 57070
        • Research Site
      • Villejuif, 프랑스, 94805
        • Research Site
      • Budapest, 헝가리, 1122
        • Research Site
      • Budapest, 헝가리, 1062
        • Research Site
      • Miskolc, 헝가리, 3526
        • Research Site
      • Szekszárd, 헝가리, 7100
        • Research Site
      • Szolnok, 헝가리, 5000
        • Research Site
      • Zalaegerszeg, 헝가리, 8900
        • Research Site
      • Birtinya, 호주, 4575
        • Research Site
      • Darlinghurst, 호주, 2010
        • Research Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

INCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants can join the trial if they:

  • Have advanced breast cancer that is not able to be treated with surgery or radiation;
  • Have an ESR1 mutation in their cancer;
  • Have breast cancer that is HR-positive and HER2-negative;
  • Are currently being treated with a CDK4/6 inhibitor and an AI and have been taking these drugs for at least 6 months;
  • Have not had their cancer get worse after taking an AI and CDK4/6 inhibitor;
  • Are able to do their daily activities;
  • Are at least 18.

Full list of inclusion criteria:

  • Proven diagnosis of adenocarcinoma of the breast with evidence of locoregionally recurrent or metastatic disease not amenable to resection or radiation therapy with curative intent;
  • Documentation of histologically confirmed diagnosis of estrogen receptor positive (ER+) /HER2- breast cancer based on local laboratory results;
  • Currently on AI (letrozole or anastrozole) + CDK4/6 inhibitor (palbociclib, abemaciclib or ribociclib) ± LHRH as the initial endocrine based treatment for advanced disease;
  • Eastern Cooperative Oncology Group performance status of 0 or 1;
  • ESR1m detected by central testing of ctDNA with Guardant360® CDx;
  • Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures;
  • Adequate organ and marrow function.

EXCLUSION CRITERIA:

INFORMATION FOR TRIAL PARTICIPANTS - Participants cannot join the trial if they:

  • Had certain types of tumors in the past that may come back;
  • Are currently taking any other treatments for their cancer or other conditions including hormone replacements, medications, or supplements that could interfere with the trial treatment;
  • Have or have had any major health problem, infection, or recent surgery that could make it difficult or dangerous to participate in this trial.

Full list of exclusion criteria:

  • Advanced, symptomatic, visceral spread, that are at risk of life-threatening complications in the short term;
  • Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease;
  • Any evidence of severe or uncontrolled systemic diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol;
  • Patient with known or family history of severe heart disease;
  • Previous treatment with AZD9833, investigational SERDs or fulvestrant;
  • Currently pregnant (confirmed with positive pregnancy test) or breastfeeding;
  • Persistent non-haematological toxicities (CTCAE Grade > 2) caused by CDK4/6 inhibitor and/or AI treatment.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: AZD9833 + palbociclib, abemaciclib or ribociclib

The patients will receive AZD9833 (75 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150,100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + anastrozole placebo (PO, once daily) or letrozole placebo (PO, once daily)

Dosage formulation: AZD9833 tablets will be administered orally

Dosage formulation: anastrozole placebo tablets will be administrated orally.

Dosage formulation: letrozole placebo tablets will be administered orally.

Dosage formulation: palbociclib tablets/capsules will be administered orally

Dosage formulation: abemaciclib tablets will be administered orally

Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Dosage formulation: ribociclib tablets will be administered orally

활성 비교기: Anastrozole or letrozole + palbociclib, abemaciclib or ribociclib

The patients will recieve anastrozole (1 mg, PO, once daily) or letrozole (2.5 mg, PO, once daily) + palbociclib (PO, once daily, 125, 100 or 75 mg for 21 consecutive days followed by 7 days off treatment), abemaciclib (PO, twice daily, 150, 100 or 50 mg) or ribociclib (To Be Determined, PO, once daily for 21 consecutive days followed by 7 days off treatment) + AZD9833 placebo (PO, once daily)

Dosage formulation: palbociclib tablets/capsules will be administered orally

Dosage formulation: abemaciclib tablets will be administered orally

Men (when medically applicable) and pre- or peri-menopausal women are required to receive a monthly LHRH agonist.

Dosage formulation: ribociclib tablets will be administered orally

Dosage formulation: AZD9833 placebo tablets will be administrated orally.

Dosage formulation: anastrozole tablets will be administered orally.

Dosage formulation: letrozole tablets will be administered orally.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival (PFS) assessed by the Investigator as defined by response evaluation criteria in solid tumors (RECIST version 1.1)
기간: From randomization until the earlier of the progression event or death (approximately 2 years)

PFS is defined as the time from randomization to objective disease progression (as assessed by RECIST 1.1) or death.

From randomization until the earlier of the progression event or death (approximately 2 years)

2차 결과 측정

결과 측정
측정값 설명
기간
Progression-free survival 2 (PFS2)
기간: From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)

PFS2 is defined as the time from the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death.

From randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy or death (approximately 3.5 years)
Overall survival (OS)
기간: From randomization until the date of death due to any cause (approximately 5 years)

The OS is defined as the time from randomization to death due to any cause.

From randomization until the date of death due to any cause (approximately 5 years)
Chemotherapy free survival
기간: From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)

Time to chemotherapy is defined as the time from randomization until the earlier of the start date of chemotherapy or death due to any cause.

From randomization until the earlier of the start date of chemotherapy or death due to any cause (approximately 5 years)
Objective response rate (ORR) assessed by the Investigator as defined by RECIST version 1.1
기간: From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)

ORR is defined as the proportion of patients who have a complete response (CR) or partial response (PR), as determined by the investigator at local site per RECIST 1.1.

From randomization until a response or in the absence of a response from randomization up until progression, or the last evaluable assessment in the absence of progression (approximately 5 years)
Clinical benefit rate at 24 weeks (CBR24)
기간: At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)

CBR at 24 weeks is defined as the percentage of participants who have a complete response (CR) or partial response or who have stable disease (SD) per RECIST 1.1 as assessed by the investigator at local site for At least 23 weeks after randomisation for each patient to allow for an early assessment within the assessment window (1 week window for RECIST assessment)

At least 23 weeks after randomisation for each patient (1 week window for RECIST assessment)
Change from baseline in EORTC QLQ-C30 scale scores
기간: From baseline until second progression (approximately 5 years)

Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Scale scores range from 0-100. For functioning and global health status/ QoL scales, higher scores indicate better functioning or global health status/QoL. For symptom scales, higher scores indicate greater symptom burden.

From baseline until second progression (approximately 5 years)
Change from baseline in EORTC QLQ-BR23 scale scores
기간: From baseline until second progression (approximately 5 years)

Change from baseline in scales scores of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-BR23). Scale scores range from 0-100. For functioning scales, higher scores indicate better functioning. For symptom scales, higher scores indicate greater symptom burden.

From baseline until second progression (approximately 5 years)
Plasma concentration of AZD9833 at specified timepoints
기간: on Day 15 for each patient

To assess the steady state PK of AZD9833 in combination with palbociclib or abemaciclib in all participants who receive at least one dose of AZD9833 per the protocol, for whom there are at least one reportable PK concentration.

on Day 15 for each patient

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2021년 6월 30일

기본 완료 (실제)

2025년 6월 30일

연구 완료 (추정된)

2028년 9월 1일

연구 등록 날짜

최초 제출

2021년 6월 30일

QC 기준을 충족하는 최초 제출

2021년 7월 14일

처음 게시됨 (실제)

2021년 7월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • D8534C00001
  • 2023-503990-39-00 (기타 식별자: EU CT number)
  • 2021-000546-17 (EudraCT 번호)
  • 2023 (미국 NIH 보조금/계약)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

IPD 공유 기간

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 액세스 기준

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .